secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2022-09-30T23:59:59+00:00
Accession:  0001193125-22-255494
Event type: other_material
Sentiment:  negative
Materiality: 0.40
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silverback Therapeutics terminates Seattle HQ lease effective Dec 31, 2022
--------------------------------------------------------------------------

- Terminated lease for ~19,829 sq ft at 500 Fairview Ave N, Seattle; lease expires Dec 31, 2022.
- No termination fee payable to landlord; lease end contingent on new tenant lease now executed.
- Tenant remains responsible for all rent through Dec 31, 2022; must surrender premises in good condition.
- Silverback grants temporary license to new tenant (Approved Licensee) for premises before termination.
- Company discloses it is undergoing a corporate merger; tenant entity will survive and remain liable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522255494/0001193125-22-255494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312522255494/d596886d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-255494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer